Yulong Xu

826 Zhangheng Road, Zhangjiang Hi Tech Park
Pudong, 201203, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Tailoring Photonic Landscape: Nanoengineering Empowers NIR-II Lanthanide Luminescence for Versatile Biomedical Applications.

Tailoring Photonic Landscape: Nanoengineering Empowers NIR-II Lanthanide Luminescence for Versatile Biomedical Applications.

Journal: Small methods

Published: May 30, 2026

Correction: Efficacy and safety of efsubaglutide alfa in individuals with type 2 diabetes (SUPER1): a randomised, double-blind, placebo-controlled, Phase IIb/III trial.

Correction: Efficacy and safety of efsubaglutide alfa in individuals with type 2 diabetes (SUPER1): a randomised, double-blind, placebo-controlled, Phase IIb/III trial.

Journal: Diabetologia

Published: March 19, 2026

Efsubaglutide alfa added to metformin improves glycaemia with β-cell functional responses in type 2 diabetes: a randomised, double-blind, placebo-controlled, two-stage adaptive phase 2b/3 trial (SUPER 2).

Efsubaglutide alfa added to metformin improves glycaemia with β-cell functional responses in type 2 diabetes: a randomised, double-blind, placebo-controlled, two-stage adaptive phase 2b/3 trial (SUPER 2).

Journal: Nature communications

Published: November 20, 2025

Efficacy, tolerability, and safety of Efsubaglutide Alfa in participants with obesity or overweight (LIGHT 1): A randomized, double-blind, placebo-controlled, ascending-dose phase 2a trial.

Efficacy, tolerability, and safety of Efsubaglutide Alfa in participants with obesity or overweight (LIGHT 1): A randomized, double-blind, placebo-controlled, ascending-dose phase 2a trial.

Journal: Diabetes, obesity & metabolism

Published: September 30, 2025

Diabetes Remission in Drug-Naïve Patients with Type 2 Diabetes After Efsubaglutide Alfa Treatment.

Diabetes Remission in Drug-Naïve Patients with Type 2 Diabetes After Efsubaglutide Alfa Treatment.

Journal: Advances in therapy

Published: September 29, 2025

Dehydration-Assisted Rapid Modulated Synthesis of Monodisperse Covalent Organic Framework Single Crystals With Tunable Sizes.

Dehydration-Assisted Rapid Modulated Synthesis of Monodisperse Covalent Organic Framework Single Crystals With Tunable Sizes.

Journal: Small (Weinheim an der Bergstrasse, Germany)

Published: August 14, 2025

Efficacy and safety of Efsubaglutide Alfa in "overrun" patients in the SUPER2 trial: A post-hoc analysis for comprehensive evaluation.

Efficacy and safety of Efsubaglutide Alfa in "overrun" patients in the SUPER2 trial: A post-hoc analysis for comprehensive evaluation.

Journal: Diabetes, obesity & metabolism

Published: July 16, 2025

Effect of Efsubaglutide Alfa on the Pharmacokinetics of Metformin and Digoxin in Healthy Participants.

Effect of Efsubaglutide Alfa on the Pharmacokinetics of Metformin and Digoxin in Healthy Participants.

Journal: Clinical pharmacokinetics

Published: May 13, 2025

Efficacy and safety of efsubaglutide alfa in individuals with type 2 diabetes (SUPER1): a randomised, double-blind, placebo-controlled, Phase IIb/III trial.

Efficacy and safety of efsubaglutide alfa in individuals with type 2 diabetes (SUPER1): a randomised, double-blind, placebo-controlled, Phase IIb/III trial.

Journal: Diabetologia

Published: May 01, 2025

Safety, pharmacokinetics and pharmacodynamics of Efsubaglutide Alfa in healthy participants: A randomised, dose-escalation phase 1 study.

Safety, pharmacokinetics and pharmacodynamics of Efsubaglutide Alfa in healthy participants: A randomised, dose-escalation phase 1 study.

Journal: Diabetes, obesity & metabolism

Published: March 13, 2025

Exposure-Response Analysis of Efsubaglutide Alfa in Patients with Type 2 Diabetes Treated with Metformin.

Exposure-Response Analysis of Efsubaglutide Alfa in Patients with Type 2 Diabetes Treated with Metformin.

Journal: Clinical pharmacokinetics

Published: March 06, 2025

Exposure-Response Analysis of Efsubaglutide Alfa in Patients with Type 2 Diabetes Mellitus.

Exposure-Response Analysis of Efsubaglutide Alfa in Patients with Type 2 Diabetes Mellitus.

Journal: Clinical pharmacokinetics

Published: March 06, 2025

Showing 1-12 of 16

Last Updated: 09/26/2026